PATENT CLAIM ANALYSIS

Application Number: 15900823
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "262100"]

Abstract:
The present invention relates to compound III and its use for treatment and/or prevention of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases such as first episode of psychosis (FEP), relapses of these diseases such as reduction of relapse in patients with schizophrenia (REX). The invention also relates to polymorphs of compound III, and pharmaceutical compositions comprising compound III and/or its polymorphs.

Claim (Index 5):
The method according to  claim 1  for treating a reduction of relapse in schizophrenia.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 88.0
- Lexical Diversity: 1.67391
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15298469', '14884397', '15818044', '14627355', '14950834']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8073078181860835
- 35 USC 102 Novelty (BERT): 0.5289873227241983
- Combined Prediction Score: 0.779475768639895
- Mean Citation Score: 329.844702
- Max Citation Score: 341.85025
- Similarity Product: 219.7978135282696

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test